{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:45:51Z","timestamp":1790642751314,"version":"4.1.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1080\/13543784.2020.1842357","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T22:27:00Z","timestamp":1603492020000},"page":"1339-1346","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug"],"prefix":"10.1080","volume":"29","author":[{"given":"Marwa","family":"Sabha","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette C.","family":"Siaton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, USA"},{"name":"Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30417-9"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31460-X"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22721"},{"issue":"6","key":"cit0004","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2019-216515","volume":"79","author":"Safiri S","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/art.39692"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2010.03.001"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.10.004"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2017.11.014"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.M.00285"},{"issue":"11","key":"cit0010","first-page":"2271","volume":"33","author":"Dillon CF","year":"2006","journal-title":"J Rheumatol"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2065::AID-ART356>3.0.CO;2-Z"},{"issue":"120","key":"cit0012","first-page":"7","volume":"37","author":"Pincus T","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"cit0013","unstructured":"Hochberg MC, Cisternas M, Watkins-Castillo S. Osteoarthritis 2019 [cited 2020 Oct 2]. Available from: https:\/\/www.boneandjointburden.org\/fourth-edition\/iiib10\/osteoarthritis"},{"key":"cit0014","unstructured":"Agency for Healthcare Research and Quality. HCUP Fast Stats. Healthcare Cost and Utilization Project (HCUP) 2019 [cited 2020 Oct 2]. Available from: https:\/\/www.hcup-us.ahrq.gov\/faststats\/NationalProceduresServlet?year1=2014&characteristic1=0&included1=0&year2=2005&characteristic2=0&included2=0&expansionInfoState=hide&dataTablesState=hide&definitionsState=hide&exportState=hide"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.04.002"},{"key":"cit0016","unstructured":"March L, Cross M, Lo C, et al. Osteoarthritis: a serious disease. OARSI org; 2016."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-3-201208070-00473"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21596"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.01.003"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32489-4"},{"issue":"4","key":"cit0021","first-page":"Cd007400","volume":"4","author":"Derry S","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"120","key":"cit0022","first-page":"3","volume":"37","author":"Hawker GA","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200970"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2938"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204194"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24131"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.11.007"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2019.06.011"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.008"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00523-9"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2017.08.015"},{"key":"cit0032","first-page":"55","volume":"131","author":"Lane NE","year":"2020","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"cit0033","doi-asserted-by":"crossref","unstructured":"Deshmukh V, O\u2019Green AL, Bossard C, et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 2019;27:1347\u20131360.","DOI":"10.1016\/j.joca.2019.05.006"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.03.004"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0411-x"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00205-8"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2015.142"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1089\/107632704323061753"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2005.03.016"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2017.07.006"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.08.007"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1002\/art.41315"},{"issue":"2","key":"cit0043","first-page":"519","volume":"78","author":"Yazici Y","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"cit0044","unstructured":"Samumed. Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis 2019\u00a0[cited 2020 Aug 18]. Available from: https:\/\/www.samumed.com\/medium\/image\/samumed-launches-phase-3-lorecivivint-sm04690-clinical-program-in-knee-osteoarthritis_556\/view.aspx"},{"key":"cit0045","unstructured":"Samumed. Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis 2019 [cited 2020 Aug 18]. Available from: https:\/\/www.globenewswire.com\/news-release\/2019\/06\/19\/1871126\/0\/en\/Samumed-Doses-First-Subject-in-Phase-3-STRIDES-X-ray-Trial-of-Lorecivivint-for-the-Treatment-of-Knee-Osteoarthritis.html"},{"key":"cit0046","unstructured":"Samumed. Lorecivivint - Samumed 2020 [cited 2020 Aug 18]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800040429"},{"key":"cit0047","unstructured":"Samumed L. Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting 2019 [cited 2020 Aug 18]. Available from: https:\/\/www.biospace.com\/article\/releases\/samumed-presents-safety-data-analysis-of-lorecivivint-for-knee-osteoarthritis-at-the-2019-acr-annual-meeting"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2020.02.588"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14735"},{"key":"cit0050","unstructured":"Yogi Berra\u2019s ~ Yogiisms quotations and quotes. [cited 2020 Aug 18]. Available from: https:\/\/www.age-of-the-sage.org\/quotations\/quotes\/yogi_berra_yogiisms.html"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1842357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:58:05Z","timestamp":1669298285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1842357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,8]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.1080\/13543784.2020.1842357"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1842357","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}